u/andres_restrepo

Which trial arm and what was the n?

Disagree on that part. 93.7% and 99.3% on the same vial is normal.

nobody should be giving this to anyone without extensive monitoring

No. This is the kind of confident post that gets copied into a screenshot and repeated for years. Where is the evidence.

Batch number and date of analysis? Both are load-bearing.

the detector wavelength matters more than people think

Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.

Yeah, 96.8% area is not the problem, the missing impurity breakdown is the problem.

Disagree. What you are describing is consistent with tapering, not with what you concluded.

The evidence standard in c/vendorvetting gets called too strict about once a month, and every time, the thread ends with the complainant agreeing.

Inter-lab variance on this kind of assay is routinely 1–2 points. Different column, different gradient, different integration.

Sceptical. If this were true we would see it reflected in the data and we do not.

ALT is where the fatty-liver story shows up first

Slight fix: the number was 99.0, not 98.9. Decimal point, but a fairly consequential one.

Asked HJ for the batch-specific COA and they sent it within six hours, full document, batch number, date, everything. That is the baseline.

the counterion is part of the mass you paid for

I love that this community will spend 40 comments on a detail. That pedantry is why the numbers here matter.

France to France: 4 days with WXT and 7 days with TFC. Same route, different carriers, variance is real.

the glucagon component changes the side effect profile, not just the efficacy

chromatogram or it did not happen